Kaló Z, Járay J, Nagy J
Novartis Hungary Ltd, Budapest, Hungary.
Prog Transplant. 2001 Sep;11(3):188-93. doi: 10.1177/152692480101100307.
Kidney transplantation is generally acknowledged as the more clinically effective and more cost-effective option in managing patients with end-stage renal disease, compared with dialysis. This study looked for confirmatory evidence in a Hungarian population.
Patients (n = 242) with end-stage renal disease who received cadaveric kidney transplantation during 1994 were followed up for 3 years. They were compared with patients (n = 840) receiving hemodialysis who were on a waiting list for transplantation. Data were collected retrospectively. Treatments were compared for clinical efficacy and for cost-effectiveness.
At month 36, the standard mortality hazard function was 3.5 times higher in the group receiving hemodialysis (P < .0001) than in the transplant recipients. Average treatment costs per patient over the 3 years were also significantly higher (P < .0001) in the hemodialysis group than in the group than received transplants. The cost of 1 year gained by transplantation was significantly less (P < .0001) than the cost associated with hemodialysis.
Compared with hemodialysis, kidney transplantation provides greater survival benefits to patients with end-stage renal disease, at less cost.
与透析相比,肾移植通常被认为是治疗终末期肾病患者更具临床疗效和成本效益的选择。本研究在匈牙利人群中寻找确证性证据。
对1994年接受尸体肾移植的终末期肾病患者(n = 242)进行了3年的随访。将他们与等待移植的接受血液透析的患者(n = 840)进行比较。数据进行回顾性收集。对治疗的临床疗效和成本效益进行比较。
在第36个月时,接受血液透析的组的标准死亡风险函数比移植受者组高3.5倍(P <.0001)。血液透析组每位患者3年的平均治疗成本也显著高于接受移植的组(P <.0001)。移植获得的1年成本显著低于与血液透析相关的成本(P <.0001)。
与血液透析相比,肾移植以更低的成本为终末期肾病患者带来更大的生存益处。